Biotechnology

Expert Intelligence Raises $4.7M Seed Round to Automate Expert Judgment in Regulated Labs

February 4, 2026 8:00 AM

Expert Intelligence™, a startup building AI systems that automate expert decision-making in regulated laboratory environments, today announced it has raised a $4.7M seed round led by Sierra Ventures with participation from TSVC and Acorn Pacific Ventures. Founded by Lalin Theverapperuma, Ph.D., a veteran AI and machine learning engineer with more than 20 years of experience at Apple, Meta, Intel, and Bosch, Expert Intelligence's platform...

Read more

Ayrmid Reports Additional New Real-World Data on Motixafortide for Stem Cell Mobilization in Sickle Cell Disease and Beta-Thalassemia

February 4, 2026 7:05 AM

Ayrmid, Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., today announced further encouraging real-world data on the use of motixafortide, a long-acting CXCR4 inhibitor licensed by Ayrmid under the brand name APHEXDA®, for mobilizing HSCs in patients with sickle cell disease undergoing gene therapy. The results were presented at the 2025 Transplantation & Cellular Therapy meetings of ASTCT® and CIBMTR® (TANDEM), taking...

Read more

Microbix Presents Molecular Pathology Platform Results

February 4, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of its novel Quality Assessment Products ("QAPs™") and platform technology for supporting the quality management and reproducibility of Molecular Pathology derived diagnoses of infectious diseases at Labquality Days, a lab diagnostics conference taking place in Helsinki, Finland from February...

Read more

BIO ESSENCE CORP (OTC Pink: BIOE) Announces Commencement of Regulation A Tier 2 Offering for up to $5.0 Million

February 3, 2026 9:00 AM

BIO ESSENCE CORP. (the "Company" or "BIOE" - (OTCID:BIOE): is a company that promotes wellness and vitality through a lifestyle supported by holistic products and practices, and it is pursuing growth strategies that include AI-enabled platform initiatives, today announced that it has commenced its Regulation A, Tier 2 offering of up to $5,000,000 of its securities. Under the Offering, the Company is offering up to 100,000,000 shares at a public...

Read more

Lobe Sciences Reports First Quarter 2026 Results and Highlights

February 3, 2026 7:00 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited financial results for the first quarter of fiscal 2026 ended November 30, 2025 (Q1:2026) and provided an update on operational progress for the quarter. "During the first quarter of fiscal 2026, Lobe meaningfully accelerated its research and...

Read more

Rarity Bioscience Announces That ARUP Laboratories Has Become the First U.S. Reference Lab To Validate Its Ultra-Sensitive superRCA Assay

February 3, 2026 4:00 AM

Sweden-based Rarity Bioscience today announced that ARUP Laboratories, a leading national reference laboratory and nonprofit enterprise of the University of Utah, has become the first commercial laboratory in the United States to validate and offer its groundbreaking superRCA™ assay for research applications. This milestone follows a year-long collaborative agreement between the two organizations, aimed at advancing high-sensitivity molecular...

Read more

SLAS Names PulpFixin(R) Official Sustainability Sponsor for Europe Conference in Vienna, Key Sustainability Supporter at SLAS2026 in Boston

February 2, 2026 12:00 PM

The Society for Laboratory Automation and Screening (SLAS) has named PulpFixin® its official Sustainability Sponsor for SLAS Europe 2026 Conference and Exhibition, and a key promoter of sustainability at SLAS2026 in Boston, establishing a global partnership focused on advancing sustainable materials and practices across life science laboratories. The designation positions PulpFixin as a sustainability partner across SLAS' flagship events,...

Read more

CEO Statement to Shareholders

February 2, 2026 9:50 AM

Reaffirming Strategic Execution and Long-Term Value Creation As the compliance deadline under the minimum bid requirement of NASDAQ approaches, we recognize that market volatility and uncertainty can weigh on investor sentiment. Periods like this often test confidence, particularly for innovation-driven companies that are building long-term value rather than optimizing for short-term optics. I want to take this opportunity to reaffirm that the...

Read more

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

February 2, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today reported it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease. The Company has approximately 23 active sites across 26 locations, and enrollment is progressing across this clinical network. IGC expects to complete enrollment by mid-2026. The...

Read more

Vibrant Wellness Expands Zoomer Portfolio with Four New Tests to Advance Longevity Medicine and Predictive Care

February 2, 2026 8:00 AM

Vibrant Wellness, a clinical research and specialty laboratory best known for its Zoomer tests, today announced a newly structured diagnostic portfolio designed to deliver the most clinically impactful insights for overall wellness, predictive medicine, and longevity. The updated menu is organized around ten comprehensive Zoomers spanning critical, functional, environmental, and foundational health domains - and includes four new tests....

Read more

Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics

February 2, 2026 7:00 AM

Bioxytran, Inc. (OTCQB:BIXT) ("Bioxytran" or the "Company"), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, announced the execution of a Sponsored Research Agreement with the University of Minnesota to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with...

Read more

Moolec Science Granted Continued Listing on Nasdaq Subject to Hearings Panel Conditions

January 30, 2026 4:20 PM

Moolec Science S.A. ("Moolec" or the "Company"), a science-based food ingredient company focused on scalable protein solutions for the global market, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to certain conditions. The Panel acknowledged that the Company satisfied the minimum bid price compliance period under Nasdaq Listing Rule...

Read more

Change in Number of Shares and Votes in Alligator Bioscience AB

January 30, 2026 9:15 AM

Alligator Bioscience (STO:ATORX) - During January 2026, the number of shares and votes in Alligator Bioscience AB ("Alligator Bioscience") has increased as a result of the rights issue of units which was resolved by the Board of Directors on 22 October 2025 and approved by the extraordinary general meeting on 25 November 2025, as well as the directed issue of units to guarantors in the rights issue resolved by the Board of Directors on 7 January...

Read more

NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer

January 30, 2026 9:00 AM

NeuroEM Therapeutics®, an award-winning clinical-stage biotechnology research company pioneering the use of radio frequencies to reverse Alzheimer's disease, announced today the addition of W. Scott Burgin, MD, to its executive team. Burgin, a longtime NeuroEM medical advisor, becomes the company's first Chief Medical Officer (CMO). "Dr. Burgin's appointment marks an exciting and important milestone for NeuroEM. His rare combination of clinical...

Read more

eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run

January 29, 2026 7:45 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - reported detailed downstream performance results from its recently completed 100-liter pilot production run of NCT. The results expand upon the previously announced 100× scale-up milestone and provide new data demonstrating manufacturability, material recovery, and product quality at...

Read more

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

January 29, 2026 6:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce positive interim results from its ongoing comparative mouse study evaluating cell penetrating peptide (CPP) enabled, needle-free delivery of GLP/GIP-based therapies. In this interim analysis, animals treated with a novel semaglutide/CPP topical formulation demonstrated reduced blood glucose following an oral glucose...

Read more

Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.

January 29, 2026 8:33 AM

Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced the expansion of its U.S. clinical site network, further strengthening its infrastructure to support its ongoing pivotal Phase III study of GelrinC® for knee cartilage repair as well as future clinical programs. "Building on our existing clinical collaborations, we are...

Read more

Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline

January 29, 2026 7:00 AM

Bioxytran, Inc. (OTCQB:BIXT) ("Bioxytran" or the "Company"), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, today issued a corporate update summarizing previously disclosed program developments and reinforcing the Company's strategic direction entering 2026. (BioXyTran) Corporate Update Highlights (Previously Disclosed) ProLectin‑M (broad-spectrum antiviral...

Read more

New Review Published in Immunotherapy Highlights the Potential for Clever-1 Inhibition with bexmarilimab to Become the Cornerstone of Next-Generation, Multi-Indication Cancer Immunotherapy

January 29, 2026 2:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces the publication of a comprehensive review article in the prestigious peer-reviewed journal, Immunotherapy. The article, titled ‘ Clinical optimization of bexmarilimab as a myeloid checkpoint therapy,' provides a definitive scientific and translational analysis of Clever-1,...

Read more

Biomind Labs Announces CAD $2.52 Million Private Placement Financing

January 27, 2026 4:15 PM

Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, is pleased to announce that it intends to complete a non-brokered private placement of up to 28,000,000 units of the Company (the "Units") at a price of $0.09per Unit for gross proceeds of up to C$2,520,000...

Read more